B8FK logo

Biofrontera AG Stock Price

XTRA:B8FK Community·€16.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

B8FK Share Price Performance

€2.61
0.11 (4.40%)
€2.61
0.11 (4.40%)
Price €2.61

B8FK Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks
0 Rewards

Biofrontera AG Key Details

€13.6m

Revenue

€2.4m

Cost of Revenue

€11.2m

Gross Profit

€17.9m

Other Expenses

-€6.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Sep 30, 2026
-1.10
82.41%
-48.98%
11.1%
View Full Analysis

About B8FK

Founded
1997
Employees
74
CEO
n/a
WebsiteView website
www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Recent B8FK News & Updates

Recent updates

No updates